Vol. 7, Issue 1, Part A (2025)

The 2019-2020 pandemic was caused by the novel coronavirus SARS-CoV-2; in this thorough study, we address the most recent literature on the virus. Beginning in bats, the virus spread to people in Wuhan, Hubei, China, on December 20, 2019, through an unidentified intermediate species. An international public health emergency was declared by the World Health Organization. The disease is spread by inhalation or contact with infectious droplets, and the incubation period lasts between two and four days. Researchers conducted a thorough analysis of the coronavirus epidemic, including a discussion of the hazards associated with the second wave and the new variety. The new version COVID-l9 was probably first introduced in India, quickly traveled around the world, and is currently the primary brand in the UK. The list of variant strains in each class is kept up to date by the Centers for Disease Control and Prevention. There are three categories of variations: High consequence variations, variants of one interest, and variants of one worry. B.l.526, B.l.525, and P.2 are the current variations that are included in the variant of interest; B.l.l.7, P.l, B.l.35l, B.l.427, and B.l.429 are included in the variant of concern. The number of instances has significantly increased after double and triple genetically altered variants were found in India. In addition to increasing the risk of transmission, morbidity, and mortality, emerging variants may also evade detection by standard or widely accessible diagnostic tests, delay diagnosis and treatment, exhibit decreased susceptibility to treatments like antivirals, monoclonal antibodies, and convalescent plasma, and cause reinfection in previously infected and recovered individuals as well as new vaccine discoveries. Therefore, in order to prevent dissemination, early discovery of mutations, avoidance of mutations, and vira1 replication, precautions, genomic surveillance, and vaccine progression are essential. The Omicron form (B.1.1.529) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was discovered in Botswana in November 2021. On November 24, it was initially reported to the World Health Organization. On November 26, 2021, the World Health Organization classified the strain as a variation of concern and gave it the name Omicron on the recommendation of scientists who are members of the Who's Technical Advisory Group on SARS-CoV-2 Virus Evolution (TAG-VE). With 50 mutations accumulating across the genome, the Omicron variation was the most severely modified strain when compared to the other four variants of concern (Alpha, Beta, Gamma, and Delta). At least 32 spike protein mutations are present in the Omicron version, which is twice as numerous as the Delta form. Research has demonstrated that, in comparison to the early wild-type strain and the other four variants of concern, having several mutations can improve the Omicron variant's infectivity and immune evasion. The Omicron variation is emerging as the predominant strain in several nations around the world, posing significant difficulties for the prevention and management of coronavirus illness in 2019. (COVID-19). In order to provide a scientific reference for monitoring, prevention, and vaccine development strategies for the Omicron variant, the current review article attempts to analyze and summarize data regarding the biological features of amino acid mutations, the epidemic characteristics, immune escape, and vaccine reactivity of the Omicron variant.